CD33-CAR-T cells have shown some clinical efficacy (7), although mature clinical results have yet to be published, and Gemtuzumab, a monoclonal antibody directed against CD33, is already approved for the treatment of AML patients (24), supporting their role as an AML target. Here, CD33 is linked to acute myeloid leukemia.